ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.730,36
-0,21%
S&P 500
5.738,17
-0,13%
US Dollar vs BRL
5,4335
-0,09%
Bitcoin
65.880,68
1,07%
Brent Oil
71,98
1,45%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) Notícias

AGEN

Agenus (AGEN)

Agenus Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AGEN
DataHoraFonteTítuloCódigoCompanhia
26/09/202406:45PR Newswire (US)AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AGENAgenus Inc
19/09/202406:45PR Newswire (US)Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN)NASDAQ:AGENAgenus Inc
16/09/202406:45PR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) ShareholdersNASDAQ:AGENAgenus Inc
13/09/202411:00Business WireBotensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024NASDAQ:AGENAgenus Inc
11/09/202415:25PR Newswire (US)AGEN INVESTOR ALERT: Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class ActionNASDAQ:AGENAgenus Inc
09/09/202408:30Business WireBotensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024NASDAQ:AGENAgenus Inc
03/09/202408:30Business WireAgenus to Participate in September Investor ConferencesNASDAQ:AGENAgenus Inc
08/08/202417:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
08/08/202417:47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AGENAgenus Inc
08/08/202417:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/08/202417:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/08/202417:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
08/08/202408:00Business WireAgenus Announces Appointment of Tom Harrison to Board of DirectorsNASDAQ:AGENAgenus Inc
08/08/202408:00Business WireAgenus Reports Second Quarter 2024 Operational and Financial ResultsNASDAQ:AGENAgenus Inc
07/08/202411:58Business WireAgenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant CancersNASDAQ:AGENAgenus Inc
26/07/202408:00Business WireAgenus to Provide Second Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
18/07/202408:00Business WireAgenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerNASDAQ:AGENAgenus Inc
28/06/202412:10Business WireSignificant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI ConferenceNASDAQ:AGENAgenus Inc
27/06/202408:30Business WireCancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical StudiesNASDAQ:AGENAgenus Inc
17/06/202408:00Business WireAgenus Announces Appointment of Dr. Jennifer Buell to Its Board of DirectorsNASDAQ:AGENAgenus Inc
13/06/202406:15Business WireNature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50NASDAQ:AGENAgenus Inc
04/06/202408:30Business WireAgenus Announces Virtual Annual Shareholders MeetingNASDAQ:AGENAgenus Inc
24/05/202418:00Business WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
23/05/202418:10Business WireBreakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual MeetingNASDAQ:AGENAgenus Inc
23/05/202408:30Business WireAgenus to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:AGENAgenus Inc
16/05/202408:30Business WireFDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal CancerNASDAQ:AGENAgenus Inc
07/05/202408:40Business WireAgenus Reports First Quarter 2024 ResultsNASDAQ:AGENAgenus Inc
01/05/202408:30Business WireAgenus Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:AGENAgenus Inc
24/04/202411:00Business WireBotensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingNASDAQ:AGENAgenus Inc
23/04/202408:30Business WireAgenus to Provide First Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AGEN

Seu Histórico Recente

USOTC
SJMHY
SJM (PK)
TG
GXE
Galapagos
NYSE
VMC
Vulcan Materials
TG
SJ3
Sherwin Williams
NASDAQ
AFJKR
Aimei Health Technology
BIT
NSCITA1G0DJ2
European Financial Stabi...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados